Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials
Agrawal A, Zhuo H, Brady S, Levitt J, Steingrub J, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Matthay MA, Liu KD. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2012, 303: l634-l639. PMID: 22865551, PMCID: PMC3469636, DOI: 10.1152/ajplung.00195.2012.Peer-Reviewed Original ResearchMeSH KeywordsAcute Lung InjuryAdultAgedAPACHEBiomarkersBronchoalveolar Lavage FluidCohort StudiesFemaleHumansInterleukin-6Interleukin-8MaleMiddle AgedPlasminogen Activator Inhibitor 1PneumoniaPredictive Value of TestsProtein CPulmonary EdemaRespiratory Distress SyndromeRespiratory InsufficiencyRisk FactorsSeverity of Illness IndexThrombomodulinConceptsAcute lung injuryVentilator-free daysPlasma plasminogen activator inhibitor-1IL-6Oxygenation indexClinical trialsPredictive valueClinical outcomesIL-8Treatment of ALIHigher APACHE II scoreHigher plasma IL-6Severe acute lung injuryRelevant outcomesBronchoalveolar lavage (BAL) biomarkersAPACHE II scorePlasma IL-6Cohort of patientsMarker of severitySimilar baseline characteristicsPoor clinical outcomePlasminogen activator inhibitor-1Future clinical trialsAssociation of plasmaActivator inhibitor-1